RemeGen readies $514M IPO as HKEX adds jewel to the crown
Nasdaq may boast of a biotech boom with the sheer number of companies in its IPO queue. But when it comes to chart-topping hauls, HKEX apparently takes the crown.
The latest record setter is RemeGen, a Yantai, Shandong-based biotech that — months after drawing in a stellar slate of crossover investors for a $100 million-plus round — is set to raise up to $514 million from its public debut in Hong Kong.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.